Making pet healthcare faster, easier and safer

Trecento Diagnostics is creating a world where urine, not blood, is used in veterinary healthcare diagnostics and where accurate molecular tests give results in minutes rather than days.

We specialise in companion animal diagnostics and zoonotic diseases

Focused research and innovation to make testing more accessible

Trecento’s procedural innovations, coupled with the drive to make testing more accessible, are enabling us to develop a range of unique and non-invasive products that use urine as the source medium. Our development pipeline includes tests for a range of zoonoses. Our current focus is Lyme disease which affects not only canine and feline pets but also humans, with an estimated 427,000 new cases of Lyme in the US every year. Scientists estimate that two million people could suffer from post-treatment Lyme disease by 2021.

Leading the way in the detection of zoonoses using urine

Zoonoses - pathogenic organisms such as bacteria or viruses which we share with animals - cause more than 60% of human infectious diseases, and have been responsible for some of the most devastating disease outbreaks in recent years, including HIV, Ebola, SARS and the current COVID-19 pandemic. Starting with Lyme disease Trecento is developing non-invasive urine tests that will greatly speed up testing, accuracy and testing availability as well as bring down costs and reduce the need for phlebotomy.
Your browser does not support SVG

Welcome to the next molecular diagnostic revolution

The molecular diagnostic field as it is defined today was established by PCR (polymerase chain reaction) technology and evolved in the laboratory medicine space. PCR has been – and still is – a phenomenal research technique, but it has proved difficult to move PCR from the central laboratory (with its specialised equipment and highly trained technicians) to small laboratories and clinics.
  • The result? To date, molecular diagnostics has not penetrated the market as much as other clinical diagnostic systems. Trecento realised that the next step in harnessing the massive benefits molecular diagnostics provides, and in driving it into everyday clinical practice, was to take a fresh, holistic approach by looking at the entire sample-to-result workflow.
    Our approach to both human and veterinary diagnostics employs innovative thinking that takes molecular testing to a whole new level, using cutting-edge Loop-Mediated Isothermal Amplification (LAMP) technology that builds significantly on PCR. Our T300 delivers a highly accurate, reliable and low-cost molecular testing platform that can test urine samples at point of care in the veterinary clinic within 40 minutes.
Your browser does not support SVG

Urine testing is now a viable alternative to blood testing

Trecento’s unique DNA extraction device now allows instrument-free DNA extraction without the need for centrifugation and offers ambient temperature delivery and storage, enabling urine testing to now be a viable alternative to blood testing.
  • For the very first time, veterinary surgeons can now quickly and easily carry out the DNA extraction protocol themselves, with no need for specialist technicians, laboratories and complex chemical DNA isolation protocols.
    Using urine rather than blood for routine testing will generate hundreds of millions of pounds' worth of savings in animal diagnostics and offer massive future potential in human healthcare by reducing specialist staff time and the cost of consumables. In human diagnostics, it will also improve patient care – especially for patients with a fear of needles and those (including many elderly patients) with whom phlebotomy is difficult.
    In companion animal diagnostics, urine samples are much easier to acquire than blood samples, thanks to our HygieCatch product, and could also help to reduce the need for risky and invasive cystocentesis procedures.

In numbers

9.9 million

Number of pet dogs owned in the UK.


Number of veterinarians in the US.


Number of Americans diagnosed with tick-borne disease each year.


Lyme disease increase each year in Europe.


Number of veterinary diagnostic tests carried out each working day in the US.


Number of pet dogs owned in the US.

Who likes needles?

For many people, particularly the elderly, having blood taken is an unpleasant and painful experience. In the veterinary world, it can also be a difficult and upsetting procedure for companion animals, their owners and vets.
That’s why Trecento’s vision is to replace the need to take blood by using urine across companion animal healthcare. Cystocentesis is the most common method of obtaining urine from dogs and cats. It carries risks that include: bladder rupture, peritonitis, abdominal vessel laceration and colon damage. HygieCatch®, Trecento’s innovative urine collection device, removes these risks.
  • HygieCatch® addresses an unmet need in veterinary diagnostics – the problem of risk-free canine urine collection. A novel, unique patented urine collection device that enables veterinarians to gain easy, risk-free access to canine urine samples, it is the first ever canine urine collection device with patented technology and a unique attractant that helps stimulate dogs to urinate.
    Having created a way to help veterinarians and pet owners collect a sample with HygieCatch®, we intend to provide canine urine-based tests for conditions such as Lyme disease via our T300 molecular testing platform. We want to help keep our four-legged friends safe, as well as human patients.
    For more information about HygieCatch® visit
Your browser does not support SVG

Our market approach may be disruptive, but millions of pets and pet owners will benefit!

Millions of canine urine samples are tested each day, at the point-of-care, for urinary tract infections and diabetes. Now these same sample specimens can be used for a wider range of tests, speeding up diagnosis, improving patient care and greatly reducing the financial burden on pet owners and insurance organisations.
  • In many parts of the world, laboratories offering microbiology are rare, and phlebotomy blood testing is not available. The use of urine rather than blood for molecular diagnostics offers the opportunity to test millions of not only companion animals but also people who would not otherwise have access to such advanced diagnostic healthcare.
    Trecento sees enormous market potential in both companion animal and human diagnostics globally. The sheer volume of current companion animal and human urinalysis testing is immense. Access to new-generation molecular diagnostics that provide greater depth and more accessible testing for zoonotic diseases will only increase this.